Announced Sun, 19 Jul · 16:29 IST
Rossari Biotech Q1 FY27: Revenue up 28% YoY to record Rs. 697.2 cr
Compliance View source PDF
ROSSARI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-3.4%1-day move
₹530.05
prior close
—
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
————-3.4-6.2-7.2-7.6-1.5—————
Up moveDown movePending
AI summary
Rossari Biotech reported its highest-ever quarterly revenue of Rs. 697.2 crore in Q1 FY27, up 28% YoY. EBITDA rose 19% to Rs. 80.6 crore, though margin slipped to 11.6% from 12.5%. PAT grew 4% to Rs. 35.1 crore. Standalone revenue jumped 32% and PAT 31%. All three segments (HPPC, TSC, AHN) grew around 27-28%. The company set up a greenfield blending facility in Thailand with 5,000 MTPA capacity and sold its Andheri office as part of non-core asset monetisation.
Likely market impact
Strong revenue growth and record quarterly performance signal healthy momentum. Margin compression remains a watch point despite business expansion.